Cribstone Capital Management LLC Holds Stake in Agilent Technologies, Inc. (A)

Cribstone Capital Management LLC held its stake in Agilent Technologies, Inc. (NYSE:A) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,359 shares of the medical research company’s stock at the end of the second quarter. Cribstone Capital Management LLC’s holdings in Agilent Technologies were worth $140,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Trust Co. of Vermont raised its stake in Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock valued at $145,000 after buying an additional 205 shares in the last quarter. CENTRAL TRUST Co raised its stake in Agilent Technologies by 15.3% in the first quarter. CENTRAL TRUST Co now owns 2,994 shares of the medical research company’s stock valued at $158,000 after buying an additional 398 shares in the last quarter. Penserra Capital Management LLC raised its stake in Agilent Technologies by 9.5% in the first quarter. Penserra Capital Management LLC now owns 3,496 shares of the medical research company’s stock valued at $184,000 after buying an additional 304 shares in the last quarter. Coconut Grove Bank raised its stake in Agilent Technologies by 84.7% in the first quarter. Coconut Grove Bank now owns 3,750 shares of the medical research company’s stock valued at $198,000 after buying an additional 1,720 shares in the last quarter. Finally, ELM Advisors LLC purchased a new stake in Agilent Technologies during the second quarter valued at approximately $202,000.

Agilent Technologies, Inc. (NYSE A) opened at 60.13 on Friday. Agilent Technologies, Inc. has a 1-year low of $42.92 and a 1-year high of $61.84. The stock has a 50 day moving average of $60.08 and a 200 day moving average of $55.15. The stock has a market capitalization of $19.32 billion, a P/E ratio of 33.80 and a beta of 1.30.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.10. The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Agilent Technologies had a net margin of 13.41% and a return on equity of 16.49%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.44 EPS. On average, analysts expect that Agilent Technologies, Inc. will post $2.23 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd were paid a dividend of $0.132 per share. The ex-dividend date was Thursday, June 29th. This represents a $0.53 annualized dividend and a dividend yield of 0.88%. Agilent Technologies’s dividend payout ratio is currently 29.78%.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was originally published by [[site]] and is owned by of [[site]]. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at [[permalink]].

Several analysts recently commented on A shares. Morgan Stanley raised their price target on shares of Agilent Technologies from $65.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday, May 24th. Jefferies Group LLC raised their price target on shares of Agilent Technologies from $59.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, May 23rd. Deutsche Bank AG reiterated a “buy” rating and issued a $66.00 target price on shares of Agilent Technologies in a research report on Thursday, June 22nd. BTIG Research lifted their target price on shares of Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. Finally, Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a research report on Tuesday, May 16th. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $60.12.

In other Agilent Technologies news, Director Paul N. Clark sold 3,866 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $59.05, for a total transaction of $228,287.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Didier Hirsch sold 5,710 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $60.60, for a total transaction of $346,026.00. The disclosure for this sale can be found here. Insiders have sold a total of 112,608 shares of company stock worth $6,737,509 over the last ninety days.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.